Tiratricol
From Wikipedia, the free encyclopedia
Tiratricol
|
|
Systematic (IUPAC) name | |
2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl] acetic acid |
|
Identifiers | |
CAS number | |
ATC code | H03 D11AX08 |
PubChem | |
Chemical data | |
Formula | C14H9I3O4 |
Mol. mass | 621.932 g/mol |
Synonyms | 3,3',5-triiodothyroacetic acid TRIAC |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | Presumed high |
Metabolism | Hepatic glucuronidation |
Half life | ? |
Excretion | Biliary |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Tiratricol (also known as TRIAC) is a thyroid hormone analogue. It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.
Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[2][3]
[edit] Legal status
Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[4]
[edit] References
- ^ Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]" (in Portuguese). Arq Bras Endocrinol Metabol 48 (1): 83–92. doi: . PMID 15611821. Free full textPDF (95.3 KiB)
- ^ U.S. Food and Drug Administration (November 21, 2000). "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol". Press release. Retrieved on 2007-08-08.
- ^ Health Canada (December 2, 1999). "Health Canada issues warning on products containing Tiratricol (TRIAC)". Press release. Retrieved on 2007-08-08.
- ^ Anvisa suspende Tiratricol (Portuguese). Brazilian Society of Endocrinology and Metabolism. Retrieved on 2007-08-08.
|
|